Overview

An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2017-11-27
Target enrollment:
Participant gender:
Summary
This prospective observational study will evaluate the safety and efficacy of first-line rituximab maintenance therapy in participants with follicular non-Hodgkin's lymphoma. Participants initiated on rituximab maintenance therapy according to the standard of care and in line with the current summary of product characteristics will be followed for a maximum of 3 years or until disease progression occurs.
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Rituximab